8-K: Beyond Air Secures $11.5 Million Loan with Warrants Issued to Lenders

Beyond Air, Inc. has finalized a $11.5 million loan agreement, issuing warrants to purchase common stock to the lenders as part of the deal.

Summary

• Beyond Air, Inc. has entered into a Loan and Security Agreement for a $11.5 million loan.
• The loan carries a 15% annual interest rate, with 3% payable in cash and 12% payable in kind until June 30, 2026, after which all interest will be paid in cash.
• The loan's principal and any accrued interest are due on October 4, 2034, if not repaid earlier.
• Starting October 1, 2026, the company will make quarterly principal repayments based on 8% of net sales, if that exceeds the accrued interest.
• If the royalty interest is less than the accrued interest, a portion of the interest will be paid in cash at 3% and in kind at 12%.
• The company has also issued warrants to purchase common stock to the lenders, with an exercise price of $0.3793 per share.
• The warrants are exercisable for five years following shareholder approval to increase the company's authorized common stock.

Sentiment

Score: 4

Explanation: The document indicates a necessary but potentially burdensome financing agreement. The high interest rate and security on all assets are concerning, while the warrants could dilute existing shareholders. The reliance on future sales for repayment adds uncertainty.

Positives

• The loan provides Beyond Air with $11.5 million in funding.
• The loan structure allows for some flexibility in early payments with a portion of interest being paid in kind.
• The loan includes a mechanism for principal repayment tied to revenue, which could accelerate repayment if sales are strong.

Negatives

• The 15% interest rate is relatively high, which could increase the company's financial burden.
• The loan is secured by substantially all of the company's assets, which could pose a risk if the company defaults.
• The warrants issued to lenders could dilute existing shareholders if exercised.

Risks

• The high interest rate could strain the company's finances, especially if sales do not meet expectations.
• The loan is secured by substantially all of the company's assets, increasing the risk of asset loss in case of default.
• The issuance of warrants could lead to dilution of existing shareholders' equity.
• The company's ability to repay the loan is dependent on future sales performance.

Future Outlook

The company's future financial performance will be significantly influenced by its ability to generate net sales, which will determine the pace of principal repayment. The company will also need to obtain shareholder approval to increase the number of authorized shares to allow for the exercise of the warrants.

Industry Context

This type of financing, involving a secured loan with warrants, is not uncommon for companies in the biotechnology or medical device sector, especially those that are still in the development or early commercialization phase. It provides immediate capital while also offering potential upside to lenders through equity participation.

Comparison to Industry Standards

• The 15% interest rate is relatively high compared to traditional bank loans, but is not unusual for venture debt or loans to companies with higher risk profiles.
• The use of warrants is a common practice in venture debt financing, allowing lenders to participate in the potential upside of the company.
• The royalty-based repayment structure is also seen in some biotech and medical device financings, aligning repayment with revenue generation.
• Comparable companies in the biotech space often use a mix of debt and equity financing to fund operations and development.

Related Party Transactions

• The loan was made by certain lenders including the company's Chief Executive Officer Steven Lisi and director Robert Carey.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• Employees may be impacted by the company's financial performance and ability to repay the loan.
• Creditors are secured by substantially all of the company's assets, which could impact their recovery in case of default.

Next Steps

• The company needs to obtain shareholder approval to increase the number of authorized shares to allow for the exercise of the warrants.
• The company will need to monitor its net sales to ensure it can meet the principal repayment obligations.
• The company will need to manage its cash flow to meet the interest payments.

Key Dates

Keywords

loan, warrants, financing, debt, common stock, interest rate, repayment, net sales, royalty interest, shareholder approval